Who are fenofibrate and tibolone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fenofibrate-and-tibolone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

fenofibrate and tibolone — Competitive Intelligence Brief

fenofibrate and tibolone (fenofibrate and tibolone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate + Selective Estrogen Receptor Modulator (SERM). Area: Cardiovascular / Women's Health.

marketed Fibrate + Selective Estrogen Receptor Modulator (SERM) PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone) Cardiovascular / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

fenofibrate and tibolone (fenofibrate and tibolone) — Keogh Institute for Medical Research. This combination product uses fenofibrate to lower triglycerides and raise HDL cholesterol via PPAR-alpha activation, while tibolone provides hormone replacement therapy through selective tissue-specific estrogenic, progestagenic, and androgenic activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fenofibrate and tibolone TARGET	fenofibrate and tibolone	Keogh Institute for Medical Research	marketed	Fibrate + Selective Estrogen Receptor Modulator (SERM)	PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate + Selective Estrogen Receptor Modulator (SERM) class)

Keogh Institute for Medical Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fenofibrate and tibolone — Competitive Intelligence Brief. https://druglandscape.com/ci/fenofibrate-and-tibolone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab